Drugs.com - Clinical Trials

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...

Mar 6, 2025 - 23:15
 0
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
Read More

Tags:

Previous Article

Pi Day at 7-Eleven: Discounts Extend Beyond Pizza

Next Article

Trump’s FDA commissioner nominee takes the hot seat

Related Posts

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer

Gradalis Secures FDA Regenerative Medicine Advanced The...

Feb 9, 2025  0

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Announces Patient Enrollment t...

Feb 9, 2025  0

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Announces Positive Topline Results From Phase...

Feb 9, 2025  0